Treatment with statins may be considered in ESRD patients for primary prevention of cardiovascular disease

Kidney International

Volumn 75, Issue 12, 2009, Pages 1354-1355

  Manca Di Villahermosa, Simone ^a,b   Taccone Gallucci, Massimo ^a,b   MacCarrone, Mauro ^c,d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF TERAMO   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REACTIVE OXYGEN METABOLITE;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE PREDISPOSITION; DRUG MECHANISM; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY FAILURE; LETTER; LIPID PEROXIDATION; MORTALITY; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; UPREGULATION;

EID: 66749091091     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.107     Document Type: Letter

References (4)

1. Cachofeiro V, Goicochea M, Gracia de Vinuesa S et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int 2008; 74(suppl 111): S4-S9.
2. Maccarrone M, Taccone Gallucci M, Meloni C et al. 'Activation of 5-lipoxygenase and related lipid peroxidation in hemodialysis patients'. J Am Soc Nephrol 1999; 10: 1991-1996.
3. Lonzi M, Manca di Villahermosa S, Summaria F et al. Cardiovascular outcome in asymptomatic haemodialysis patients submitted to aggressive medical therapy: a 30-month follow-up. Nephrol Dial Transplant 2007; 22s6: vi322-vi323.
4. Akmal M. Hemodialysis in diabetic patients. Am J Kidney Dis 2001; 38(suppl 1): S195-S199.